Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.65 |
| ▸ | MAPT | P10636 | 6/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29957473 | 0.80 | ALDH1A1 (0.97) | ALDH1A1L3MBTL1MAPTPOLBGAA | |
| SCHEMBL29957359 | 0.79 | ALDH1A1 (1.00) | ALDH1A1L3MBTL1MAPTPOLBGAA | |
| SCHEMBL15331618 | 0.79 | ALDH1A1 (1.00) | ALDH1A1L3MBTL1MAPTPOLBGAA | |
| SCHEMBL3961043 | 0.76 | ALDH1A1 (0.60) | ALDH1A1L3MBTL1MAPTPOLBGAA | |
| SCHEMBL5131549 | 0.73 | KDM4E (0.62) | ALDH1A1MAPTPOLBGAAKMT2A | |
| SCHEMBL2820859 | 0.73 | KMT2A (0.53) | ALDH1A1MAPTGAAKMT2ASMN1; SMN2 | |
| SCHEMBL14142352 | 0.72 | ALDH1A1 (0.64) | ALDH1A1L3MBTL1MAPTPOLBGAA | |
| SCHEMBL14142353 | 0.72 | ALDH1A1 (0.64) | ALDH1A1L3MBTL1MAPTPOLBGAA | |
| SCHEMBL890634 | 0.71 | MAPT (0.55) | ALDH1A1L3MBTL1MAPTPOLBGAA | |
| SCHEMBL2574902 | 0.70 | GAA (0.69) | ALDH1A1L3MBTL1MAPTPOLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079737-A1 | PYRIDOPYRIMIDINONE COMPOUNDS USEFUL IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | XENON PHARMACEUTICALS INC. (CA) | 2009-07-22 | — | — | EP | disclosed |
| US-20080194616-A1 | PYRIDOPYRIMIDINONE COMPOUNDS USEFUL IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | XENON PHARMACEUTICALS INC. (CA) | 2008-08-14 | — | — | US | disclosed |
| WO-2008097991-A1 | PYRIDOPYRIMIDINONE COMPOUNDS USEFUL IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | XENON PHARMACEUTICALS INC. (CA) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194616-A1 | PYRIDOPYRIMIDINONE COMPOUNDS USEFUL IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | SCN1A, SCN3A, SCN1B | ALDH1A1 1009/4885L3MBTL1 2597/4885MAPT 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.